Related Experiment Video
Updated: May 7, 2026

03:53
Extracellular Vesicle Tissue Factor Activity Assay
Published on: December 29, 2023
An acquired, calcium-dependent, factor X inhibitor
1Division of Hematology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Blood Cells, Molecules & Diseases
|October 1, 2013
Summary
A rare acquired factor X deficiency was caused by a calcium-dependent antibody that targets factor X. This antibody also recognized prothrombin and factor VII, impacting diagnostic tests.
Area of Science:
- Hematology
- Immunology
- Coagulation Disorders
Background:
- Acquired factor X (FX) deficiency is a rare bleeding disorder.
- It is often associated with autoantibodies, but anti-FX antibodies are infrequently detected.
- This case describes a patient with severe bleeding due to a specific anti-FX antibody.
Observation:
- A patient presented with severe bleeding.
- The bleeding was attributed to a calcium ion-dependent anti-FX IgG antibody.
- The purified antibody bound the light chain of FX, requiring calcium ions for enhanced binding (>1000-fold).
Findings:
- The antibody demonstrated cross-reactivity with prothrombin (100-fold lower affinity) and factor VII (1000-fold lower affinity).
- In functional assays, increasing phospholipid concentrations reduced the antibody's inhibitory activity, similar to lupus anticoagulants.
- The antibody's binding was dependent on the γ-carboxyglutamic acid domain of FX.
Implications:
- Understanding the antibody's characteristics is crucial for accurate laboratory diagnosis of acquired FX deficiency.
- The calcium-dependency and phospholipid interactions offer insights into the antibody's mechanism of action.
- This case highlights the importance of considering specific autoantibodies in unexplained bleeding disorders.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
X-Inactivation
The human X chromosome contains over ten times the number of genes as in the Y chromosome. Since males have only one X chromosome, and females have two, one might expect females to produce twice as many of the proteins, with undesirable results.

